When the portfolio grows faster than the team
As portfolios grow, internal teams may be managing multiple assets, studies and development stages while coordinating specialist providers across clinical operations, regulatory affairs, CMC, safety and biometrics.
Add a specialist function or extend your delivery team when you need additional capacity. We work within your established processes and governance, keeping priorities, dependencies and delivery risks visible. This helps your team maintain oversight without adding another management layer.
Biotech & Pharma Clients
The capabilities your portfolio needs
Bring in one specialist function or connect several capabilities around the same programme. We shape the team around the work to be done.
Plan the programme
We connect clinical development strategy, European regulatory planning, scientific advice and medical oversight to keep decisions aligned across the product lifecycle.
Run the studies
We deliver first-in-human, early phase and Phase I–III studies, connecting Clinical Operations, biometrics and vendor management within one delivery model. Our capabilities also include bioavailability and bioequivalence studies.
Add capacity where you need it
Keep ownership of your programme while adding the specialist functions, regional support or operational capacity your team needs. We work within your existing model and adapt as portfolio demands change.
Why small and mid-sized pharma work with Clarenta
Knowledge carries into the next study
Where we support more than one study, we retain programme knowledge across the relationship. Your team spends less time repeating the product history, systems and decisions already made.
Senior people stay close
Senior team members remain involved, with a named lead connecting decisions to their operational, regulatory and budget implications.
One team as needs change
Move from strategic or regulatory support into early phase work or wider clinical delivery without rebuilding the operating model at every stage.
Clear responsibility
We agree ownership, interfaces and escalation routes from the start, so your team knows who is responsible for each part of delivery.
The pressure
Your team still needs to understand what depends on what, where decisions are required and whether every workstream supports the same regulatory and commercial objectives.
Our response
Your team retains the strategic decisions. We keep the clinical, regulatory, CMC, safety, biometrics and external-provider workstreams connected around the same programme objectives.
Site strategy starts with patients
We assess where relevant patients can realistically be reached and whether sites can deliver the protocol before recommending a country and site plan.
Risks are discussed early
When a decision, dependency or scope change may affect delivery, we explain it early and make the implications visible.
Three ways to work with Clarenta
Full-service delivery
Regional delivery
Rescue and redirection
Explore our therapeutic area capabilities
What our clients say
Case study: Exceeding recruitment targets in a Phase II asthma study
Clarenta supported patient recruitment and clinical monitoring across three sites in Bulgaria for a Phase II proof-of-concept study in adults with moderate-to-severe asthma.
The three sites enrolled 48 participants. The leading site recruited 29 participants against a target of 15, exceeding its recruitment target by 93%.
FAQs
Yes. You can engage Clarenta for one function, several capabilities or full-service delivery. We can work within your existing systems and processes where appropriate, so additional capacity does not require a separate operating model.
Yes. Clarenta can take responsibility for defined countries, functions or activities while working within the governance and systems of your existing programme. Responsibilities and interfaces are agreed at the beginning.
Clarenta supports clinical trial delivery across Western, Central and Eastern Europe, the Baltics, the Caucasus and Central Asia. The appropriate country and delivery model is assessed during feasibility.
We discuss proposed scope changes before they are implemented or invoiced. Your project lead explains the operational, timeline and budget implications so your team can make an informed decision.
Yes. Our capabilities include clinical pharmacology, PK/PD study design, bioavailability and bioequivalence studies, and development support through to authorisation. We confirm the appropriate analytical model during study planning.
Yes. We support sponsors that need European regulatory and operational capability without building a full internal European organisation. Legal representation and country-specific requirements are confirmed during planning.